Actively Recruiting
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
Led by Nanjing Leads Biolabs Co.,Ltd · Updated on 2026-03-12
178
Participants Needed
25
Research Sites
172 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of LBL-024 combined with etoposide and platinum in the first-line treatment of patients with advanced neuroendocrine carcinoma (NEC)
CONDITIONS
Official Title
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Agree to follow the trial treatment regimen and visit schedule, voluntarily enroll, and sign the written informed consent.
- Aged 18-75 years at the time of signing informed consent.
- Eastern Cooperative Oncology Group (ECOG) physical status score of 0 or 1.
- Expected survival time of at least 12 weeks.
- Have at least one measurable target lesion according to RECIST 1.1 criteria.
- Fertile men and women of childbearing age willing to use effective contraception from informed consent until 6 months after last dose; women must have a negative pregnancy test within 7 days before first dose.
You will not qualify if you...
- Major organ surgery (excluding needle biopsy) or significant trauma within 4 weeks before first dose, or need for elective surgery during the trial.
- Use of immunomodulatory drugs within 14 days before first dose, including thymosin, interleukin, or interferon.
- Active infection requiring intravenous anti-infective treatment.
- Clinically uncontrollable pleural or pericardial effusion needing repeated drainage or intervention.
- History of immunodeficiency including positive HIV antibody.
- Pregnant or breastfeeding women.
- Other conditions judged by the investigator to affect compliance or suitability for the study.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 25 locations
1
Anhui Provincial Hospital
Hefei, Anhui, China, 230001
Actively Recruiting
2
Anhui Cancer Hospital
Hefei, Anhui, China, 230031
Actively Recruiting
3
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
4
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
5
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
6
Fujian Cancer Hospital
Fuzhou, Fujian, China, 350014
Actively Recruiting
7
Sun Yat-sen University Cancer Center (SYSUCC)
Guangzhou, Guangdong, China, 510060
Actively Recruiting
8
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, Guangdong, China, 510080
Actively Recruiting
9
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China, 530021
Actively Recruiting
10
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150081
Actively Recruiting
11
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China, 471003
Actively Recruiting
12
Henan Cancer Hospital
Zhengzhou, Henan, China, 450008
Actively Recruiting
13
Hubei Cancer Hospital
Wuhan, Hubei, China, 430079
Actively Recruiting
14
Xiangyang Central Hospital
Xiangyang, Hubei, China, 441000
Actively Recruiting
15
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Actively Recruiting
16
Liaoning Cancer Hospital
Shenyang, Liaoning, China, 110801
Actively Recruiting
17
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250063
Actively Recruiting
18
Shandong Cancer Hospital
Jinan, Shandong, China, 250117
Actively Recruiting
19
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
20
Shanxi Cancer hospital
Taiyuan, Shanxi, China, 030013
Actively Recruiting
21
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610044
Actively Recruiting
22
The First Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
23
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
24
Sir Run Run Shaw Hospital，Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310016
Actively Recruiting
25
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China, 310022
Actively Recruiting
Research Team
L
lin shen
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here